Company intelligence / Profile preview

GalChimia

Ownership: Private
Employees: ~55
Development stage: Preclinical

Overview

GalChimia is a leading European CRO specializing in organic synthesis and medicinal chemistry. It provides R&D services supporting the discovery and preclinical development of small molecules for pharmaceutical, biotech, agrochemical, and related industries. The company has contributed to multiple international consortia projects—including small molecule programs for prostate cancer—but does not itself sponsor clinical trials or own proprietary drugs in advanced stages.

Therapeutic areas: OncologyCardiovascularNeurologyInfectious Diseases
Modalities: Small moleculePeptides
Industry: Drug Discovery Services

Partnerships

Applus+ LGAIApplus+ groupNuCapCure consortium partnerIteria BiopharmaUniversity of Santiago de Compostela

Beyond the preview

Go deeper on GalChimia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GalChimia.

Explore the full profile